Table 1. Demographic and clinical characteristics of the study participants.
| Cilostazol (n=205) | Aspirin (n=408) | P value | |
|---|---|---|---|
| Age (year) | 63.9±10.2 | 62.9±8.8 | 0.242 |
| Men | 161 (78.5%) | 331 (81.1%) | 0.447 |
| BMI (kg/m2) | 25.1±2.6 | 25.0±2.8 | 0.946 |
| Hypertension (%) | 133 (64.9%) | 258 (63.2%) | 0.690 |
| Hyperlipoidemia (%) | 11(16.0%) | 28(16.0%) | 0.474 |
| Diabetes (%) | 56 (27.3%) | 115 (28.2%) | 0.821 |
| Stroke (%) | 11 (5.4%) | 24 (5.9%) | 0.795 |
| Current smoker (%) | 79 (38.5%) | 170 (41.7%) | 0.457 |
| Previous percutaneous coronary intervention | 55 (26.8%) | 101 (24.8%) | 0.625 |
| Clinical diagnosis | |||
| Stable angina | 139 (67.8%) | 272 (66.7%) | 0.777 |
| ACS | 66 (32.2%) | 136 (33.3%) | 0.777 |
| Systolic BP (mm Hg) | 128.2±14.1 | 126.3±16.8 | 0.158 |
| Diastolic BP (mm Hg) | 77.5±9.2 | 76.4±9.6 | 0.213 |
| ALT | 30.4±28.4 | 31.7±25.6 | 0.602 |
| Creatinine (μmol/L) | 80.1±21.1 | 82.0±46.4 | 0.585 |
| Hemoglobin (g/L) | 134.3±22.1 | 131.1±25.6 | 0.134 |
| Hematocrit (%) | 40.0±4.2 | 39.2±7.7 | 0.159 |
| PLT (X109/L) | 206.1±71.8 | 206.1±72.1 | 0.999 |
| LVEF (%) | 61.9 ± 8.7 | 61.0 ± 8.8 | 0.28 |
| Medication | |||
| Clopidogrel | 205 (100%) | 408 (100%) | 1.00 |
| GP IIb/IIIa | 39 (19.0%) | 82 (20.1%) | 0.753 |
| Statins | 199 (97.1%) | 394 (96.6%) | 0.881 |
| β-block | 164 (80.0%) | 327 (80.1%) | 0.827 |
| ACEI/ARB | 133 (64.9%) | 270 (66.2%) | 0.659 |
| Nitrates | 119 (58.0%) | 237 (58.1%) | 0.911 |
BMI, Body Mass Index; ALT, Alanine Transaminase; PLT, Platelet; LVEF, Left Ventricular Ejection Fraction; GP IIb/IIIa, Glycoprotein IIb/IIIa; ACEI, Angiotensin Converting Enzyme Inhibitors; ARB, Angiotensin Receptor Blocker.